Maqola

Prevalence and epidemiology of hepatitis C in Uzbekistan – results from a population-based serosurvey, 2022

Shaun ShadakerDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, USAElizaveta JoldasovaIntegral Global Health, Tashkent, UzbekistanRania A. TohmeDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, USAAybek KhodievDivision of Global Health Protection, Centers for Disease Control and Prevention, Uzbekistan Country Office, Tashkent, UzbekistanShakhida KaramatovaDivision of Global Health Protection, Centers for Disease Control and Prevention, Uzbekistan Country Office, Tashkent, UzbekistanNataliya KanResearch Institute of Virology of the Republican Specialized Scientific and Practical Medical Centre of Epidemiology, Microbiology, Infectious and Parasitic Diseases, Tashkent, UzbekistanAbdulaziz AbdurasulovResearch Institute of Virology of the Republican Specialized Scientific and Practical Medical Centre of Epidemiology, Microbiology, Infectious and Parasitic Diseases, Tashkent, UzbekistanBotirjon KurbanovCommittee for Sanitary and Epidemiological Welfare and Public Health, Ministry of Health of the Republic of Uzbekistan, Tashkent, UzbekistanZulfiya AbdurakhimovaTashkent Medical Academy, Department of Public Health and Management, Tashkent, UzbekistanDilafkor MirdjalilovDivision of Global Health Protection, Centers for Disease Control and Prevention, Uzbekistan Country Office, Tashkent, UzbekistanSaleem KamiliDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, USANino KhetsurianiDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, USAErkin MusabaevResearch Institute of Virology of the Republican Specialized Scientific and Practical Medical Centre of Epidemiology, Microbiology, Infectious and Parasitic Diseases, Tashkent, Uzbekistan

2026en

Ochiq kirishOltin

Litsenziya: cc-by

ABI

Annotatsiya

Objectives Uzbekistan launched a national viral hepatitis elimination program in 2022, but precise estimates of hepatitis C prevalence are needed to guide elimination efforts. In 2022, we conducted a cross-sectional population-based seroprevalence survey among adults (aged ≥18 years) and children (aged 5–17 years) in Uzbekistan to estimate the prevalence and epidemiology of hepatitis C. Methods Interviewers collected information on demographics and potential exposures to hepatitis C virus (HCV). Blood samples were tested for HCV antibodies (anti-HCV) and, if positive, HCV RNA. We calculated weighted prevalence estimates and 95% confidence intervals (CI) and assessed factors associated with HCV exposure and infection using multivariable logistic regression. Results Overall, 9,066 adults and 4,087 children were tested for hepatitis C. The prevalence of anti-HCV and HCV RNA among adults was 3.9% (95% CI: 3.3–4.6) and 2.0% (95% CI: 1.6–2.6), respectively, and among children was 1.1% (95% CI: 0.5–2.2) and 0.5% (95% CI: 0.2–1.0), respectively. Prevalence of anti-HCV and HCV RNA increased with age. Ever having surgery or an invasive medical procedure (adjusted odds ratio [aOR] 1.65 [95% CI: 1.09–2.50]), and past incarceration (aOR 4.88 [95% CI: 1.46–16.29]) were associated with HCV exposure and history of invasive dental procedures (aOR 2.63 [95% CI: 1.11–6.22]) and receipt of a tattoo (aOR 3.84 [95% CI: 1.57–9.38]) were associated with chronic infection. Conclusions Uzbekistan could consider nationwide HCV screening focusing first on older age groups and incarcerated persons, and implementing infection prevention and control measures in healthcare settings to help prevent future infections.

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.1016/j.ijregi.2026.100968

Iqtiboslar va manbalar

0 ta iqtibos11 ta foydalanilgan manba